Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights

Eledon's Tegoprubart Shows Efficacy, Gains Orphan Drug Status

Eledon Pharmaceuticals announced its first quarter 2026 financial results and significant business updates for its lead investigational product, tegoprubart. Key highlights include 100% insulin independence achieved in 10 out of 12 patients with high-risk type 1 diabetes following allogenic islet transplantation in an investigator-led trial at UChicago Medicine. Additionally, tegoprubart received FDA Orphan Drug designation for preventing allograft rejection in liver transplantation. The company also reported positive 24-month follow-up data from a Phase 1b long-term extension study in kidney transplantation, showing no acute rejection and improved graft function. Eledon ended the quarter with $111.1 million in cash, cash equivalents, and short-term investments.

• An ongoing investigator-led trial at UChicago Medicine evaluating tegoprubart in 12 adults with high-risk type 1 diabetes undergoing islet transplantation demonstrated remarkable efficacy. All 10 patients who were more than four weeks post-transplant achieved 100% insulin independence, with no signs of graft rejection, de novo donor-specific HLA antibodies, or common tacrolimus-associated toxicities like nephrotoxicity, hypertension, or neurotoxicity.
• The U.S. Food and Drug Administration (FDA) granted Orphan Drug designation to tegoprubart for its potential in preventing allograft rejection in liver transplantation. This designation acknowledges the significant unmet medical need in this area and could provide certain development incentives and market exclusivity upon approval.
• Long-term 24-month follow-up data from eight patients in the Phase 1b trial long-term extension study of tegoprubart in kidney transplantation showed a favorable safety and efficacy profile. Patients experienced no episodes of biopsy-proven acute rejection, graft loss, death, new-onset diabetes mellitus, or de novo donor-specific antibody formation. Furthermore, mean estimated glomerular filtration rate (eGFR) improved from 67.0 mL/min/1.73 m2 at 12 months to 74.2 mL/min/1.73 m2 at 24 months.

Tegoprubart Achieves Insulin Independence in Type 1 Diabetes Islet Transplant

The VX-880-101 FORWARD study represents a significant advancement in Type 1 diabetes treatment through allogeneic stem cell-derived islet cell therapy. This Phase 1-2 trial evaluated zimislecel, administered as either half-dose (0.4×10 cells) in Part A or full-dose (0.8×10 cells) in Parts B and C via single portal vein infusion, combined with glucocorticoid-free immunosuppressive therapy. Among 14 participants who completed at least 12 months of follow-up, all demonstrated successful engraftment and islet function, evidenced by detectable C-peptide levels that were previously undetectable at baseline. The efficacy results were particularly striking, with all 12 participants in the full-dose cohorts achieving freedom from severe hypoglycemic events and glycated hemoglobin levels below 7%, while spending over 70% of time in the target glucose range (70-180 mg/dL).

The insulin independence outcomes from the zimislecel study were remarkable, with 10 of 12 participants (83%) in the full-dose cohorts achieving complete freedom from exogenous insulin use at day 365. From a safety perspective, neutropenia emerged as the most common serious adverse event, affecting three participants. Two deaths occurred during the study period, including one from cryptococcal meningitis and another from severe dementia with agitation due to progression of pre-existing neurocognitive impairment, highlighting the importance of careful patient selection and monitoring in immunosuppressed populations receiving cell therapy.

Recent teplizumab studies have demonstrated the therapeutic potential of targeting autoimmunity in early-stage Type 1 diabetes. This anti-CD3 monoclonal antibody has shown consistent efficacy in delaying progression from stage 2 to stage 3 Type 1 diabetes by a median of 2 years in both pediatric and adult populations with multiple islet autoantibodies and early dysglycemia. The therapy demonstrates optimal effectiveness when initiated before significant β-cell loss occurs, preserving insulin secretion capacity and reducing the risk of progression to clinical diabetes with an adjusted hazard ratio of 0.41 (95% CI 0.22-0.78). Safety profiles across multiple studies have been generally favorable, with adverse effects characterized as mild and transient, supporting its FDA approval in November 2022 for delaying the onset of stage 3 Type 1 diabetes in high-risk individuals.

Expanding Tegoprubart's Potential Across Organ Transplantation

Beyond its investigation in Type 1 diabetes, tegoprubart is being evaluated across multiple therapeutic areas, demonstrating the versatility of CD40L pathway inhibition. The clinical development program encompasses both neurological and transplantation indications with distinct study designs tailored to each condition's requirements.

• Amyotrophic Lateral Sclerosis (ALS): A multicenter dose-escalating open-label Phase 2A study enrolled 54 participants across 4 dose cohorts (1 mg/kg, 2 mg/kg, 4 mg/kg, and 8 mg/kg), with participants receiving 6 intravenous infusions every 2 weeks to assess safety, tolerability, and impact on pro-inflammatory biomarkers

• Kidney Transplantation: Human trials are currently underway investigating tegoprubart's potential for rejection prophylaxis, leveraging its CD40L-targeting mechanism that has demonstrated promising efficacy and safety profiles in preventing transplant rejection

• Preclinical Transplantation Research: Studies in pancreas transplantation using nonhuman primate models were conducted but proved unsuccessful, providing important learnings for the broader transplantation development strategy

• Clinical Outcomes Data: The ALS study achieved a 90.7% completion rate (49 of 54 subjects) and demonstrated dose-dependent reductions in pro-inflammatory chemokines and cytokines, with tegoprubart appearing safe and well-tolerated across all dose levels tested

Addressing Unmet Needs in Type 1 Diabetes and Transplant Immunosuppression

Despite decades of research and therapeutic advances, type 1 diabetes remains a complex condition without a cure, presenting significant challenges across multiple treatment modalities. Current approaches face fundamental limitations that prevent optimal disease management and patient outcomes. The field continues to grapple with both established therapeutic barriers and emerging complications as new interventions are developed.

• Insulin therapy limitations - Standard insulin therapy cannot maintain blood glucose concentrations within the narrow physiological range achieved by normal pancreatic beta cells, fails to solve all problems in autoimmune diabetes, and requires patients to adapt to demanding regimens while remaining at risk for potentially fatal complications

• Absence of curative treatments - Permanent remission has not been satisfactorily achieved despite various approaches including islet transplantation, beta cell regeneration, and insulin gene therapy, with no oral medications available for the approximately 2 million individuals with T1D in the U.S. who remain dependent on insulin injections or pumps

• Inadequate metabolic control - Few pediatric patients achieve their metabolic targets, and T1D remains life-threatening with severe complications and increased mortality despite modern therapeutic techniques

• Immunosuppressive approach insufficiency - Decades of focus on immunosuppressive and immunomodulatory therapies have proven insufficient after disease onset, requiring combination approaches that also address beta cell health to achieve therapeutic effectiveness

• Islet transplantation barriers - Limited availability of human islets from cadaveric pancreata, difficulty overcoming persistent autoimmune responses that destroy transplanted cells, and compromised encapsulated islet graft capability due to encapsulating material stability and longevity issues

• Beta cell regeneration obstacles - Persistent hostile autoimmune environments destroy regenerated beta cells, while insulin gene therapy lacks regulatory systems that provide glucose-responsive insulin expression and release with satisfactory kinetics

• Clinical trial and safety gaps - Trials investigating causal treatments including autoimmune blockade and cell transplantation require additional research to establish efficacy and safety profiles for widespread clinical implementation

Tegoprubart: A Pivotal Step Towards Tolerance in Transplantation

The recent updates on tegoprubart from Eledon Pharmaceuticals signal a potentially transformative shift in transplant immunosuppression. The remarkable achievement of 100% insulin independence in a significant proportion of high-risk type 1 diabetes patients following islet transplantation is particularly noteworthy. This success directly addresses a critical challenge in islet transplantation, where conventional immunosuppressive agents are known to inhibit insulin secretion and carry substantial long-term side effects. The pursuit of therapies that minimize beta-cell toxicity while preventing rejection has been a long-standing goal, and tegoprubart, as a CD40L-targeting costimulation blocker, appears to be making significant strides in this direction, aligning with the broader scientific quest for immune tolerance.

Beyond islet transplantation, tegoprubart's FDA Orphan Drug designation for liver transplantation and positive 24-month data in kidney transplantation underscore its broad potential across solid organ transplant indications. These developments align with the growing strategic imperative to move towards calcineurin inhibitor (CNI)-free regimens, which aim to mitigate the severe nephrotoxicity, cardiovascular, and metabolic complications associated with traditional immunosuppressants. The literature consistently highlights the need for such alternatives to improve long-term graft and patient survival.

However, while promising, the path forward involves careful consideration. The long-term durability of insulin independence and graft function, as well as the comprehensive safety profile of tegoprubart, particularly in larger, controlled studies, will be crucial. Comparative efficacy against established CNI-based regimens and other emerging costimulation blockers must be rigorously demonstrated. Furthermore, as with any immunosuppressive agent, the potential for infection and immunogenicity requires vigilant monitoring. Nevertheless, tegoprubart's progress represents a compelling advancement in the quest for more targeted, less toxic, and potentially tolerance-inducing immunosuppression, offering a glimpse into a future where transplant recipients can achieve better long-term outcomes with fewer systemic burdens.